The molecular and genetic basis of tumor recurrence is complex and poorly 27 understood. RIPK3 is a key effector in programmed necrotic cell death and, therefore, 28 its expression is frequently suppressed in primary tumors. In a transcriptome profiling 29 between primary and recurrent breast tumor cells from a murine model of breast 30 cancer recurrence, we found that RIPK3, while absent in primary tumor cells, is 31 dramatically re-expressed in recurrent breast tumor cells by an epigenetic mechanism. 32 Unexpectedly, we found that RIPK3 knockdown in recurrent tumor cells reduced 33 clonogenic growth, causing cytokinesis failure, p53 stabilization, and repressed the 34 activities of YAP/TAZ. These data uncover a surprising role of the pro-necroptotic 35 RIPK3 kinase in enabling productive cell cycle during tumor recurrence. Remarkably, 36 high RIPK3 expression also rendered recurrent tumor cells exquisitely dependent on 37 extracellular cystine and undergo programmed necrosis upon cystine deprivation. The 38 induction of RIPK3 in recurrent tumors unravels an unexpected mechanism that 39 paradoxically confers on tumors both growth advantage and necrotic vulnerability, 40 providing potential strategies to eradicate recurrent tumors. 41 42 43 44 45 46 47 48
49

Introduction
Epigenetic regulation of Ripk3 in the primary vs. recurrent tumor cells 152 To understand the basis of the Ripk3 mRNA upregulation in the recurrent tumor Ripk3 knockdown triggers mitotic defects and p53 activation 179 Given the unexpected robust expression of RIPK3 in the recurrent tumors, we 180 further investigated its functional role in recurrent tumor cells. First, we performed 181 clonogenic assay to determine whether silencing Ripk3 in primary or recurrent tumors 182 affects their capacity to proliferate and form colonies ( Figure 3A Figure 1A -B). We found that Ripk3 knockdown by two independent shRNAs 184 significantly reduced colony formation in the recurrent tumor cells ( Figure 3A-B ), but 185 not in the primary cells (Supplemental Figure 1A-B ). These data suggest that RIPK3 186 is crucial for the proliferation and survival of recurrent tumor cells. Figure 3C ). We found downregulation of several mitotic well as the depletion of the reactome to mitosis geneset by GSEA ( Figure 3D ). Hippo is off, YAP/TAZ is localized in the nucleus and able to interact with TEAD and 231 leads to downstream gene expression 36 . We found that Ripk3 silencing in recurrent 232 tumor cells led to a depletion of YAP/TAZ signature by GSEA ( Figure 4A ). RT-PCR 233 confirmed that two canonical YAP/TAZ target genes: Ctgf and Cyr61, were 234 dramatically repressed upon Ripk3 knockdown ( Figure 3C and Figure 4B ). In addition, Figure 5B ). In contrast, the primary tumor 266 cells still maintained ~50% viability even at 0.625 µM of cystine ( Figure 5B ).
Ripk3 knockdown represses YAP/TAZ pathways
267
Collectively, these cell viability assays consistently showed that recurrent tumor cells 268 are much more sensitive to cystine deprivation. 269 Alternatively, we examined whether primary and recurrent breast tumor cells 270 have different sensitivity to erastin, a potent xCT inhibitor. Consistently, we found 271 recurrent tumor cells, when compared with primary tumor cells, were more sensitive to erastin-induced cell death examined by crystal violet staining ( Figure 5C ) and 273 CellTiter-Glo assay ( Figure 5D ). While recurrent tumor cells were largely eliminated 274 between 0.5~1 µM erastin, the primary cells survived more than 8 µM of erastin with 275 ~75% viability ( Figure 5D ). Such recurrent-specific erastin sensitivities are further 276 confirmed by the higher levels of protease release in the recurrent tumor cells an 277 indication of cell membrane breakage and death ( Figure 5E ).
278
Thus, we further analyzed the protein expression of RIPK3 and MLKL in primary 279 and recurrent tumor cell lines after erastin treatment. We found that RIPK3 protein is 280 only expressed in recurrent tumor cells and modestly elevated by erastin treatment 281 (Supplemental Figure 2A ). An upregulated base level of phosphorylated MLKL is 282 noted in recurrent tumor cells when comparing to primary tumor cells (Supplemental 283 Figure 2A ). Moreover, silencing of Ripk3 abolished the MLKL phosphorylation 284 (Supplemental Figure 2B) . Therefore, the elevated RIPK3 proteins and constitutive 285 MLKL phosphorylation may prime the recurrent tumor cells to cell death triggered by 286 erastin or cystine deprivation.
287
Erastin is considered to trigger to cell death by ferroptosis, a programmed cell 288 death distinct from apoptosis and programmed necrosis 42 . However, at low dose of 289 erastin, we have previously found that necrosis pathway and RIPK3 is also required 290 for programmed cell death 16 . Given the elevated RIPK3 in recurrent tumor cells, we 291 further determined the cell death mechanisms. In addition to low dose of erastin, we 292 used different inhibitors to define the cell death mechanisms caused by erastin. We 293 found that the apoptosis inhibitor Z-Vad did not rescue the erastin-induced death. In 294 contrast, both ferroptosis inhibitor (ferrostatin-1) 44 and necrosis inhibitor (necrostatin-295 5) 45 robustly rescued the cell death, suggesting the potential role of RIPK3 in the cell 296 death triggered by erastin ( Figure 5F ). While the requirement for RIPK3 may not be generally applicable to all erastin-induced cell death, RIPK3 may be particularly critical 298 in the recurrent tumor cells with high RIPK3 expression and constitutive MLKL 299 phosphorylation.
301
Ripk3 over-expression contribute to the recurrent-specific cystine addiction 302 To examine whether high Ripk3 expression in recurrent tumor cells contributes 303 to its vulnerability to cystine deprivation, we knocked down Ripk3 by two independent 304 shRNAs and found a significant reduction of erastin-induced cell death with ~70-80% 305 of viability ( Figure 6A ), while erastin (1 µM) eliminated the control recurrent tumor cells 306 to less than 10% cell viability ( Figure 6A ). Similar results were also obtained by crystal 
